tradingkey.logo

Quantum BioPharma Ltd

QNTM

27.800USD

+4.100+17.30%
Fechamento 08/04, 16:00ETCotações atrasadas em 15 min
75.37MValor de mercado
PerdaP/L TTM

Quantum BioPharma Ltd

27.800

+4.100+17.30%
Mais detalhes de Quantum BioPharma Ltd Empresa
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Informações da empresa
Código da empresaQNTM
Nome da EmpresaQuantum Biopharma Ltd
Data de listagemMay 29, 2018
CEODr. Lakshmi P. Kotra, Ph.D.
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 29
Endereço55 University Ave. , Suite 1003
CidadeTORONTO
Bolsa de valoresCanadian Securities Exchange - CSE Listed
PaísCanada
Código postalM5J 2H7
Telefone14168548884
Sitehttps://www.quantumbiopharma.com/
Código da empresaQNTM
Data de listagemMay 29, 2018
CEODr. Lakshmi P. Kotra, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.11K
+6.97%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
106.76K
+0.66%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+9.30%
Ashwini Joshi,
Ashwini Joshi,
Director of Pharmaceutical Development
Director of Pharmaceutical Development
--
--
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Mr. Kevin Cassidy
Mr. Kevin Cassidy
Vice President - Quality of Lucid
Vice President - Quality of Lucid
--
--
Dr. Andrzej Chruscinski, M.D., Ph.D.
Dr. Andrzej Chruscinski, M.D., Ph.D.
Vice President - Clinical and Scientific Affairs
Vice President - Clinical and Scientific Affairs
--
-100.00%
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.11K
+6.97%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
106.76K
+0.66%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+9.30%
Ashwini Joshi,
Ashwini Joshi,
Director of Pharmaceutical Development
Director of Pharmaceutical Development
--
--
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 25 de jul
Atualizado em: sex, 25 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Malone Wealth Ventures LLC
21.76%
Saeed (Zeeshan)
3.10%
Durkacz (Anthony)
2.80%
Carroll (Donal)
2.37%
AdvisorShares Investments, LLC
1.28%
Other
68.68%
Investidores
Investidores
Proporção
Malone Wealth Ventures LLC
21.76%
Saeed (Zeeshan)
3.10%
Durkacz (Anthony)
2.80%
Carroll (Donal)
2.37%
AdvisorShares Investments, LLC
1.28%
Other
68.68%
Tipos de investidores
Investidores
Proporção
Investment Advisor
23.49%
Individual Investor
9.23%
Corporation
0.37%
Investment Advisor/Hedge Fund
0.22%
Hedge Fund
0.08%
Other
66.61%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
50
1.05M
34.28%
+341.83K
2025Q1
50
413.46K
17.05%
-229.58K
2024Q4
44
604.87K
28.35%
+138.76K
2024Q3
45
583.17K
30.09%
+414.87K
2024Q2
43
126.91K
14.87%
-21.03K
2024Q1
47
105.72K
14.06%
-57.49K
2023Q4
49
159.35K
26.32%
+20.22K
2023Q3
52
164.58K
27.23%
+48.13K
2023Q2
52
164.21K
27.10%
+38.85K
2023Q1
56
112.96K
18.07%
-21.18K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Malone Wealth Ventures LLC
610.37K
20.82%
+610.37K
--
Jun 23, 2025
Saeed (Zeeshan)
118.11K
4.03%
+7.69K
+6.97%
Apr 03, 2025
Durkacz (Anthony)
106.06K
3.62%
+7.69K
+7.82%
Apr 03, 2025
Carroll (Donal)
90.41K
3.08%
+7.69K
+9.30%
Apr 03, 2025
AdvisorShares Investments, LLC
48.99K
1.67%
-283.32K
-85.26%
Mar 31, 2025
Kotra (Lakshmi)
29.57K
1.01%
+7.69K
+35.15%
Apr 03, 2025
J.W. Cole Advisors, Inc.
12.59K
0.43%
+12.59K
--
Mar 31, 2025
Global X Investments Canada Inc.
8.24K
0.28%
-1.31K
-13.73%
Feb 29, 2024
Saeed (Rehan)
6.79K
0.23%
-2.15K
-24.09%
Dec 31, 2024
Xorax Family Trust
6.79K
0.23%
--
--
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
AdvisorShares Psychedelics ETF
9.02%
AdvisorShares Psychedelics ETF
Proporção9.02%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Aug 12, 2024
Merger
65<1
Aug 12, 2024
Merger
65<1
Aug 12, 2024
Merger
65<1
Aug 12, 2024
Merger
65<1
Data
Tipo
Proporção
Aug 12, 2024
Merger
65<1
Aug 12, 2024
Merger
65<1
Aug 12, 2024
Merger
65<1
Aug 12, 2024
Merger
65<1
KeyAI